The present invention provides 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1H-pyrazol-3-yl}propanoicacid in crystalline form. The present invention further provides methods for treating disorders associated with DP1, FP, TP, EP1 and EP4 prostaglandin (PG) receptors.